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The inFLUenza Patient Reported Outcome (FLU-PRO) measure is a daily diary assessing
signs/symptoms of influenza across six body systems: Nose, Throat, Eyes, Chest/Respira-
tory, Gastrointestinal, Body/Systemic, developed and tested in adults with influenza.
Objectives
This study tested the reliability, validity, and responsiveness of FLU-PRO scores in adults
with influenza-like illness (ILI).
Methods
Data from the prospective, observational study used to develop and test the FLU-PRO in
influenza virus positive patients were analyzed. Adults ( 18 years) presenting with influenza
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symptoms in outpatient settings in the US, UK, Mexico, and South America were enrolled,
tested for influenza virus, and asked to complete the 37-item draft FLU-PRO daily for up to
14-days. Analyses were performed on data from patients testing negative. Reliability of the
final, 32-item FLU-PRO was estimated using Cronbach’s alpha (α; Day 1) and intraclass
correlation coefficients (ICC; 2-day reproducibility). Convergent and known-groups validity
were assessed using patient global assessments of influenza severity (PGA). Patient report
of return to usual health was used to assess responsiveness (Day 1–7).
Results
The analytical sample included 220 ILI patients (mean age = 39.3, 64.1% female, 88.6%
white). Sixty-one (28%) were hospitalized at some point in their illness. Internal consistency
reliability (α) of FLU-PRO Total score was 0.90 and ranged from 0.72–0.86 for domain
scores. Reproducibility (Day 1–2) was 0.64 for Total, ranging from 0.46–0.78 for domain
scores. Day 1 FLU-PRO scores correlated ( 0.30) with the PGA (except Gastrointestinal)
and were significantly different across PGA severity groups (Total: F = 81.7, p<0.001; sub-
scales: F = 6.9–62.2; p<0.01). Mean score improvements Day 1–7 were significantly greater
in patients reporting return to usual health compared with those who did not (p<0.05, Total
and subscales, except Gastrointestinal and Eyes).
Conclusions
Results suggest FLU-PRO scores are reliable, valid, and responsive in adults with influ-
enza-like illness.
Introduction
Influenza (flu) is characterized by an array of symptoms, including chills, cough, sore throat, runny
or stuffy nose, fatigue, muscle/body aches, and potentially diarrhea and vomiting, with symptoms
ranging in severity and duration [1]. In the absence of known influenza virus, this constellation of
symptoms can be caused by a variety of other viruses and is often diagnosed as influenza-like ill-
ness (ILI) [2]. While most patients recover from ILI, the symptoms can negatively impact daily
activities and functioning. Symptoms of ILI often closely approximate influenza symptoms such
that the two previously have been indistinguishable. Therefore, a symptommeasure useful in influ-
enza may also be useful for evaluating the presence and severity of symptoms of ILI.
The InFLUenza Patient-Reported Outcome (FLU-PRO) measure was designed to evaluate
the presence, severity, and duration of influenza symptoms in clinical trials. Developed using
good research practices for scale development methods [3–5], including those recommended
by the US Food and Drug Administration (FDA) [6], this 32-item daily diary offers a compre-
hensive evaluation of symptoms commonly experienced by patients with influenza that can be
completed in5 minutes. While other measures of influenza symptom severity exist, such as
the Flu-iiQ [7] and the Canadian Acute Respiratory Illness and Flu Scale (CARIFS) [8], these
measures do not assess the full range of symptoms associated with varied strains of influenza
and identified as important to the patients themselves [9]. Additionally, the CARIFS was devel-
oped for use in children, while the FLU-PRO was developed for studies of adults and children,
with content validity shown in both groups [9]. Previous research demonstrated that the FLU-
PRO is reliable, valid, and responsive to change in hospitalized and non-hospitalized adults
with laboratory-confirmed influenza [10]. The purpose of these analyses was to test the
FLU-PRO validation in ILI patients
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reliability, validity, and responsiveness of FLU-PRO scores in patients with influenza symp-
toms and testing negative for the influenza virus.
Materials and methods
Study design
Data from the prospective, observational FLU-PRO development study conducted with
informed consent, under the National Institute of Allergy and Infectious Diseases institutional
review board approval, and in accordance with the Declaration of Helsinki, were used in these
analyses. Methods and results of the primary analyses in those with laboratory-confirmed
influenza are reported elsewhere [10].
Briefly, adults 18 years of age seeking medical care for acute influenza symptoms at partic-
ipating clinics in the US (16 sites; English-speaking), Argentina (two sites; Spanish-speaking),
United Kingdom (one site; English-speaking), and Mexico (three sites; Spanish-speaking)
were recruited during clinic visits. An elevated body temperature of 100˚F [37.8˚C] or greater
was not an enrollment requirement. All study participants were tested for influenza using
rapid influenza diagnostic tests (RIDTs), including polymerase chain reaction, rapid antigen
test, and/or viral culture by nasal or nasopharyngeal swab. The performance of the FLU-PRO
in those testing positive are presented elsewhere [10]. Data from subjects testing negative for
the influenza virus were included in the current analysis.
In addition to the influenza diagnostic test, consented patients completed assessments of
sociodemographic and clinical characteristics at baseline and a daily diary for 14 days that
included the 37-item draft FLU-PRO symptom diary and nine additional questions used for
FLU-PRO validation. At the Mexico site, the diary was completed via telephone interview with
data entered directly into a web-based portal by the interviewer. Patients in 16 US sites, one
UK site, and one Argentina site completed the survey either via interviewer-administration or
self-administration via a web-based system using the subject’s personal web-enabled device.
Compliance with ethical standards
The studies were conducted in accordance with the Declaration of Helsinki, and the National
Institute of Allergy and Infectious Diseases ethics committee/institutional review board
requirements, and good clinical practice guidelines. Informed consent was obtained from all
individual participants included in the study.
Instruments: Patient-reported Outcomes (PROs)
InFLUenza Patient-Reported Outcome (FLU-PRO). The final FLU-PRO questionnaire
instructed respondents to rate the severity of 32 influenza symptoms over the past 24 hours.
The presence and severity of influenza signs and symptoms are assessed across six body sys-
tems affected by influenza: Nose (4 items), Throat (3 items), Eyes (3 items), Chest/Respiratory
(7 items), Gastrointestinal (4 items), and Body/Systemic (11 items). A total score quantifies
symptoms overall. Respondents are asked to rate each sign or symptom on a 5-point ordinal
severity scale, with higher scores indicating a more severe sign or symptom. The questionnaire
was developed for self-report or interviewer-administration, with slight differences in the
instructions applicable for each administration.
Development procedures addressing content validity of the FLU-PRO are described else-
where [9]. Quantitative item reduction and validation testing were performed on data from a
prospective validation study, with data from laboratory-confirmed influenza positive patients
(N = 221) serving as the primary analytical sample [10].
FLU-PRO validation in ILI patients
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Patient Global Assessments (PGA). The Patient Global Rating of Flu Severity is a single
item to assess participants’ overall influenza symptom severity. Participants were asked to rate
severity on the following scale: 0 (“No flu symptoms today”), 1 (“Mild”), 2 (“Moderate”), 3
(“Severe”), and 4 (“Very severe”). The Patient Global Assessment of Interference in Daily
Activities is a single item to assess interference in daily activities due to influenza symptoms
during that day. Participants rated interference on the following scale: 1 (“Not at all”), 2 (“A lit-
tle bit”), 3 (“Somewhat”), 4 (“Quite a bit”), and 5 (“Very much”). The Patient Global Assess-
ment of Health is a single item to assess general physical health during that day. Participants
rated their physical health on the following scale: 1 (“Poor”), 2 (“Fair”), 3 (“Good”), 4 (“Very
good”), and 5 (“Excellent”). Finally, a Patient Global Rating of Change in Flu Severity was used
to identify stable patients for reproducibility assessment.
Return to “usual” health and activities. Patients were asked to respond (yes/no) to the
following questions: “Have you returned to your usual health today?” and “Have you returned
to your usual activities today?”
Statistical analyses
Statistical tests were performed in accordance with classical test theory [11] to evaluate the psy-
chometric properties of the FLU-PRO total and domain scores in participants with ILI, includ-
ing reliability, construct and known-groups validity, and responsiveness. These analyses were
performed on the entire ILI cohort and stratified by hospitalization status.
Reliability (internal and test-retest). Cronbach’s coefficient alpha was used to estimate
internal consistency reliability of the FLU-PRO Total and domain scores on day 1. Coefficients
of 0.7–0.9 were pre-specified as “good” internal consistency, 0.4–<0.7 as moderate, and<0.4
as low or poor [11,12].
Data from patients whose influenza severity was unchanged over time were used to estimate
the test-retest reliability of FLU-PRO Total and domain scores. Stable subjects were defined as
those with “no change” on the Patient Global Rating of Change in Flu Severity over two conse-
cutive days during Week 1 (i.e., day 1 to day 2, day 2 to day 3, etc.). If a subject was missing
FLU-PRO scores for one of the days in the planned comparison, data for this subject was
excluded from that analytical pair. Intraclass correlation coefficients (ICC from a fixed-effects
model), paired t-tests, and effect size (ES) were calculated to evaluate score reliability. ICCs
were expected to be at least moderate, exceeding 0.60. Mean differences between the two
observations were expected to be minimal with a small ES (<0.20).
Construct validity. The relationship between the FLU-PRO Total and domain scores and
three global ratings were assessed using Spearman correlations (rs) using day 1 data, hypothe-
sizing that the relationship between FLU-PRO scores and these global ratings would be moder-
ate to high (rs>0.30) [13]. Correlations with the Patient Global Rating of Flu Severity were
hypothesized to be strongest, while weaker correlations were expected with the more distal
constructs, including the Patient Global Rating of Physical Health and the Patient Global
Assessment of Interference with Daily Activities.
Known-groups validity. Analysis of variance (ANOVA) was used to compare FLU-PRO
Total and domain scores across three Patient Global Rating of Flu Severity categories at day 1:
“None” or “Mild”; “Moderate”; and “Severe” or “Very severe”. Mean (SD), F-scores, and p-val-
ues were reported to determine the magnitude of the differences. Pairwise comparisons
between means were performed using Scheffe’s test adjusting for multiple comparisons.
Responsiveness. Analysis of covariance (ANCOVA) was used to compare changes in
FLU-PRO scores at day 7 in responders (those returning to usual health or activity) and
non-responders (those not returning to usual health or activity), adjusting for day 1 scores.
FLU-PRO validation in ILI patients
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Responders were defined using the two different anchors in two separate analyses. It was
expected that responders would have significantly larger (p<0.05) change scores than non-
responders.
Exploratory analyses. Exploratory analyses were conducted to statistically compare the
symptom profiles of ILI patients in the current analytic sample at day 1 to the influenza posi-
tive patients in the FLU-PRO development sample. Specifically, independent samples t-tests
were used to compare mean FLU-PRO total and domain scores between all ILI patients overall
(i.e., hospitalized, and non-hospitalized) versus all influenza positive patients overall, while a
2-way analysis of variance (ANOVA) was used to compare mean FLU-PRO scores by influ-
enza (i.e., positive, and negative) and hospitalization (i.e., hospitalized, and non-hospitalized)
status. Scheffe’s test was used to assess pairwise comparisons between groups.
Results
Sample
Of the 536 subjects enrolled in the study, 441 had the minimum required data (day 1 diary
assessment and 1 post-day 1 diary entry); data from the 220 subjects testing negative for the
influenza virus were used in the current study. Table 1 presents baseline demographic and
clinical characteristics for the analytical sample. The majority of the participants (70.9%) were
from non-US countries.
Evaluation of psychometric properties
Results for the entire sample are reported below; results stratified by hospitalization status are
provided in the online supplement S1 File.
Descriptive statistics of FLU-PRO domain and Total scores. The distributional charac-
teristics of the FLU-PRO domain and Total scores on day 1 are shown in Table 2. Mean
domain scores were lowest for the Gastrointestinal domain (mean = 0.5; SD = 0.7) and highest
for the Nose (mean = 1.5; SD = 1.0) and Throat (mean = 1.5; SD = 1.2) domains. Floor effects
were found for the Gastrointestinal (47%) domain. No ceiling effects were found.
Reliability (internal and test-retest). Internal consistency reliability (Cronbach’s alpha)
was high for all domains (Nose = 0.80, Throat = 0.84, Eyes = 0.79, Chest/Respiratory = 0.75,
Gastrointestinal = 0.72; Body/Systemic = 0.86) and the Total score (0.90).
Two-day test-retest reliability during Week 1 are shown in Table 3. Across all two-day
assessment periods, FLU-PRO Score ICC and ES estimates were strong. Score reproducibility
early in the evaluation (between days 1 and 2) was lowest (Total: 0.64), while reproducibility in
the latter days (2–3, 4–5, 5–6) were higher (Total: 0.90, 0.89, 0.88, respectively).
Construct validity. As shown in Table 4, at day 1 the strongest associations were observed
between FLU-PRO domain and Total scores and the Patient Global Rating of Flu Severity (rs =
0.31–0.68, p<0.0001), except Gastrointestinal (rs = 0.19, p<0.05). Moderate to high correla-
tions were also found between FLU-PRO scores and the Patient Global Rating of Physical
Health for all scores (rs = -0.30–-0.49) except Gastrointestinal (rs = -0.21), Nose, and Eyes
(both rs = -0.28). Only associations between the Patient Global Assessment of Interference in
Daily Activities and the Total score (rs = 0.36, p<0.0001) and Body/Systemic domain score
(rs = 0.40, p<0.0001) were moderate to strong.
Known-groups validity. Significant differences in FLU-PRO total scores were found
across patient groups according to the patient global symptom severity rating (F = 81.7, p<
0.001). Mean [SD] scores were lowest in the No/Mild Symptoms group (0.81 [0.45]), followed
by the Moderate (1.28 [0.48]) and Severe/Very Severe groups (1.84 [0.49]). All pairwise com-
parisons using Scheffe’s test were statistically significant (p<0.001). A similar pattern of mean
FLU-PRO validation in ILI patients
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Mean (SD) 32.7 (13.0) 42.1 (15.1)
Median (Min-Max) 27.5 (19–67) 39.0 (20–91)
>65 1 (1.6%) 12 (7.7%)
Sex, n (%)
Female 41 (64.1%) 100 (64.1%)
Ethnicity, n (%)
Hispanic or Latino 5 (7.8%) 152 (97.4%)
Not Hispanic or Latino 59 (92.2%) 4 (2.6%)
Race, n (%)
Asian 2 (3.1%) 0 (0%)
Black or African American 21 (32.8%) 0 (0%)
White or Caucasian (Mestizo) 0 (0%) 152 (97.4%)
White 39 (60.9%) 4 (2.6%)
Other 2 (3.1%) 0 (0%)
Employment Status, n (%)
Employed, full time 19 (29.7%) 81 (51.9%)
Employed, part-time 0 (0%) 20 (12.8%)
Homemaker 1 (1.6%) 23 (14.7%)
Student 0 (0%) 13 (8.3%)
Unemployed 0 (0%) 11 (7.1%)
Retired 0 (0%) 1 (0.6%)
Disabled 0 (0%) 3 (1.9%)
Other 0 (0%) 2 (1.3%)
Missing 44 (68.8%) 2 (1.3%)
Military Status, n (%)
Never in the military 0 (0%) 153 (98.1%)
Active 16 (25.0%) 0 (0%)
Retired 1 (1.6%) 0 (0%)
Reserves 0 (0%) 1 (0.6%)
Other 1 (1.6%) 0 (0%)
Missing 46 (71.9%) 2 (1.3%)
Highest Level of Education
Elementary/primary school 0 (0%) 15 (9.6%)
Secondary/high school 5 (7.8%) 54 (34.6%)
Some college 7 (10.9%) 8 (5.1%)
College degree 4 (6.3%) 55 (35.3%)
Postgraduate degree 5 (7.8%) 13 (8.3%)
Other 43 (67.2%) 11 (7.1%)
Current Treatments, n (%)
Oseltamivir (Tamiflu) 4 (6.3%) 17 (10.9%)
Amantadine (Symmetrel) 0 (0%) 6 (3.8%)
Other 15 (23.4%) 93 (59.6%)
None 45 (70.3%) 52 (33.3%)
Co-morbidities, n (%)
(Continued)
FLU-PRO validation in ILI patients
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values was demonstrated for all FLU-PRO domain scores. Further, pairwise comparisons for
each domain score showed a similar pattern to the Total score, with the exception of the No/
Mild symptoms versus Moderate for the Chest/Respiratory and Gastrointestinal domains, and
Moderate versus Severe/Very Severe for the Nose domain, which were in the correct direction
but nonsignificant (p>0.05) (Table 5).
Responsiveness. Change in FLU-PRO total and domain scores across time are shown in
Fig 1, demonstrating a reduction in mean scores across days 1–14. In support of responsive-
ness, mean total and domain change scores were significantly greater for patients reporting a
return to usual health (responders) by day 7, compared to those who did not, with the excep-
tion of the Eyes and Gastrointestinal domains (Table 6). Using patient’s report of return to







None 44 (68.8%) 67 (42.9%)
Asthma 8 (12.5%) 14 (9.0%)
Chronic Obstructive Pulmonary Disease (COPD) 0 (0%) 3 (1.9%)
Osteoporosis 0 (0%) 4 (2.6%)
Depression 1 (1.6%) 14 (9.0%)
Hypertension 2 (3.1%) 28 (17.9%)
Raised cholesterol 1 (1.6%) 18 (11.5%)
Stomach ulcers 0 (0%) 5 (3.2%)
Heart attack/angina 0 (0%) 5 (3.2%)
Diabetes 3 (4.7%) 20 (12.8%)
Kidney disease 2 (3.1%) 10 (6.4%)
Lung disease 0 (0%) 8 (5.1%)
Tuberculosis 0 (0%) 3 (1.9%)
Other 6 (9.4%) 46 (29.5%)
1Other countries include Mexico (n = 154), Argentina (n = 1), and UK (n = 1).
https://doi.org/10.1371/journal.pone.0194180.t001
Table 2. FLU-PRO domain and total score descriptive statistics Day 1.






Nose 2181 1.5 ± 1.0 0.0–3.8, 1.5 (0.3) 20 (9.2%) 0 (0.0%) 2 (0.9%)
Throat 2181 1.5 ± 1.2 0.0–4.0, 1.3 (0.3) 26 (11.9%) 5 (2.3%) 2 (0.9%)
Eyes 2181 0.9 ± 1.0 0.0–4.0, 0.7 (0.0) 61 (28.0%) 3 (1.4%) 2 (0.9%)
Chest/
Respiratory
2181 1.4 ± 0.8 0.0–3.7, 1.3 (1.3) 9 (4.1%) 0 (0.0%) 2 (0.9%)
Gastrointestinal 219 0.5 ± 0.7 0.0–3.5, 0.3 (0.0) 103 (47.0%) 0 (0.0%) 1 (0.5%)
Body/Systemic 219 1.4 ± 0.9 0.0–3.6, 1.3 (0.7) 2 (0.9%) 0 (0.0%) 1 (0.5%)
Total Score 2181 1.3 ± 0.6 0.0–3.1, 1.2 (0.7) 0 (0.0%) 0 (0.0%) 2 (0.9%)
Note: higher FLU-PRO scores = more severe symptoms.
1 One item was found missing.
Abbreviations: SD = Standard Deviation
https://doi.org/10.1371/journal.pone.0194180.t002
FLU-PRO validation in ILI patients
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Table 3. Two-day test-retest reliability of FLU-PRO scores duringWeek 1 (Days 1 to Day 7).











Day 1 to Day 2
Nose 50 1.8 (1.0) 1.7 (0.9) 0.1 (0.6) 1.05 0.3010 0.09 0.78
Throat 50 1.7 (1.2) 1.4 (1.1) 0.3 (0.9) 2.26 0.0283 0.26 0.65
Eyes 50 1.0 (1.0) 1.0 (0.9) 0.1 (0.8) 0.52 0.6041 0.06 0.65
Chest/Respiratory 50 1.4 (0.8) 1.3 (0.7) 0.0 (0.6) 0.51 0.6142 0.05 0.73
Gastrointestinal 50 0.4 (0.7) 0.3 (0.5) 0.1 (0.6) 1.31 0.1965 0.16 0.46
Body/Systemic 50 1.4 (0.7) 1.2 (0.7) 0.3 (0.7) 2.68 0.0099 0.37 0.50
Total Score 50 1.3 (0.5) 1.2 (0.5) 0.2 (0.4) 2.56 0.0136 0.29 0.64
Day 2 to Day 3
Nose 44 1.4 (0.8) 1.4 (0.8) 0.1 (0.4) 0.84 0.4042 0.07 0.86
Throat 44 1.4 (1.2) 1.2 (0.9) 0.2 (0.8) 1.58 0.1210 0.15 0.74
Eyes 44 0.8 (0.8) 0.7 (0.9) 0.1 (0.7) 0.84 0.4037 0.11 0.70
Chest/Respiratory 44 1.4 (0.8) 1.5 (0.8) -0.1 (0.5) -1.25 0.2191 0.13 0.78
Gastrointestinal 45 0.4 (0.7) 0.4 (0.5) -0.0 (0.6) -0.39 0.6958 0.05 0.55
Body/Systemic 44 1.1 (0.8) 1.0 (0.7) 0.1 (0.4) 1.97 0.0550 0.16 0.83
Total Score 44 1.1 (0.6) 1.1 (0.6) 0.1 (0.3) 1.34 0.1859 0.08 0.90
Day 3 to Day 4
Nose 41 1.3 (0.9) 1.3 (0.9) 0.0 (0.5) 0.00 1.0000 0.00 0.82
Throat 41 1.3 (1.1) 1.0 (1.0) 0.3 (0.6) 2.52 0.0158 0.23 0.79
Eyes 41 0.7 (0.9) 0.5 (0.7) 0.2 (0.7) 1.47 0.1485 0.19 0.56
Chest/Respiratory 41 1.4 (0.8) 1.4 (0.7) 0.0 (0.5) 0.29 0.7727 0.03 0.81
Gastrointestinal 42 0.2 (0.3) 0.2 (0.4) 0.0 (0.4) 0.38 0.7026 0.07 0.46
Body/Systemic 42 0.9 (0.8) 0.8 (0.5) 0.1 (0.6) 0.79 0.4361 0.09 0.63
Total Score 41 1.0 (0.6) 0.9 (0.5) 0.1 (0.4) 1.19 0.2407 0.12 0.75
Day 4 to Day 5
Nose 30 0.9 (0.8) 0.8 (0.6) 0.1 (0.4) 1.27 0.2156 0.11 0.86
Throat 30 0.7 (0.9) 0.8 (0.9) -0.1 (0.7) -0.44 0.6649 0.06 0.72
Eyes 30 0.5 (0.8) 0.3 (0.6) 0.2 (0.5) 2.34 0.0264 0.25 0.76
Chest/Respiratory 30 1.1 (0.6) 1.0 (0.7) 0.1 (0.3) 1.28 0.2092 0.13 0.86
Gastrointestinal 31 0.2 (0.4) 0.3 (0.5) -0.1 (0.3) -0.94 0.3536 0.15 0.69
Body/Systemic 31 0.7 (0.6) 0.7 (0.7) -0.0 (0.4) -0.71 0.4824 0.08 0.83
Total Score 30 0.7 (0.5) 0.7 (0.5) 0.0 (0.2) 0.42 0.6787 0.04 0.89
Day 5 to Day 6
Nose 32 0.8 (0.6) 0.8 (0.6) -0.0 (0.4) -0.22 0.8249 0.03 0.76
Throat 32 0.7 (1.1) 0.7 (1.0) 0.0 (0.2) 1.07 0.2922 0.04 0.98
Eyes 32 0.4 (0.7) 0.4 (0.6) 0.0 (0.5) 0.24 0.8154 0.03 0.71
Chest/Respiratory 32 1.0 (0.7) 1.0 (0.8) 0.0 (0.5) 0.10 0.9182 0.01 0.79
Gastrointestinal 32 0.3 (0.4) 0.2 (0.4) 0.0 (0.3) 0.67 0.5089 0.09 0.70
Body/Systemic 32 0.7 (0.6) 0.6 (0.6) 0.1 (0.3) 1.99 0.0554 0.17 0.87
Total Score 32 0.7 (0.5) 0.7 (0.5) 0.0 (0.2) 1.09 0.2861 0.09 0.88
Day 6 to Day 7
Nose 27 0.8 (0.7) 0.9 (0.6) -0.1 (0.4) -0.74 0.4637 0.08 0.83
Throat 27 0.7 (0.9) 0.8 (0.9) -0.1 (0.5) -0.66 0.5181 0.07 0.86
Eyes 27 0.2 (0.3) 0.2 (0.3) -0.0 (0.2) -0.27 0.7873 0.04 0.64
Chest/Respiratory 27 1.0 (0.7) 1.1 (0.6) -0.1 (0.5) -0.88 0.3885 0.12 0.70
Gastrointestinal 27 0.1 (0.3) 0.1 (0.2) -0.0 (0.2) -0.63 0.5372 0.07 0.82
(Continued )
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were significantly greater for responders, while all other comparisons failed to reach statistical
significance (p>0.05).
Exploratory comparisons between influenza positive and ILI patient scores
Patients with confirmed influenza had statistically significantly greater symptom severity at
day 1 compared to patients with ILI, including FLU-PRO Total (p<0.0001), Nose (p<0.05),
Chest/Respiratory (p<0.0001), Gastrointestinal (p<0.01), and Body/Systemic scores (p<
0.0001) (Table L and Figure C in S1 File). The Throat and Eyes domains were not significantly
different between groups (p>0.05). Scores were also examined by hospitalization status. In
those not hospitalized, ILI patients reported significantly greater Throat scores than the influ-
enza positive patients (p = 0.0174); while the influenza positive patients reported significantly
greater Chest/Respiratory, Body/Systemic, and Total scores compared to ILI patients (p<0.05)
(Figure D in S1 File). Among hospitalized patients, those with confirmed influenza reported
significantly greater Nose, Gastrointestinal, Body/Systemic, and Total score compared to ILI
patients (all p<0.05) (Figure E in S1 File). In addition, for both patients with confirmed influ-
enza and ILI, the Patient Global Rating of Flu Severity scores decreased from day 1 to 14, as
was seen with FLU-PRO total and domain scores (Figure F in S1 File).
Discussion
The objective of this study was to assess the performance properties of the FLU-PRO in
patients seen in the clinic with ILI and testing negative for the influenza virus. For FDA qualifi-
cation purposes, the FLU-PRO was developed and tested in patients with acute, laboratory-
confirmed influenza, with scores exhibiting sound measurement properties in the sample
overall and stratified by hospitalization status. This current study tested the properties of
Table 3. (Continued)











Body/Systemic 27 0.5 (0.5) 0.3 (0.3) 0.1 (0.3) 2.26 0.0325 0.27 0.73
Total Score 27 0.6 (0.4) 0.6 (0.3) 0.0 (0.2) 0.24 0.8106 0.02 0.85
1Number of study participants with no change in flu symptom at day Y. Stable subjects were defined as those with “no change” on the Patient Global Rating of Change
in Flu Severity using two consecutive days.
2Mean difference = average Day X FLU-PRO score average Day Y FLU-PRO score (ex. Day 1 score Day 2 score); p value from paired t-test.
https://doi.org/10.1371/journal.pone.0194180.t003
Table 4. Construct validity: FLU-PRO scale correlations with other PROmeasures at Day 1.
Domains and Total Score, r (p-value)1






Patient Global Rating of Flu Severity2 0.44⇤⇤⇤ 0.47⇤⇤⇤ 0.48⇤⇤⇤ 0.31⇤⇤⇤ 0.19⇤ 0.63⇤⇤⇤ 0.68⇤⇤⇤
Patient Global Rating of Physical Health3 -0.28⇤⇤⇤ -0.31⇤⇤⇤ -0.28⇤⇤⇤ -0.30⇤⇤⇤ -0.21⇤ -0.43⇤⇤⇤ -0.49⇤⇤⇤
Patient Global Assessment of Interference in Daily Activities4 0.07 0.11 0.17⇤ 0.27⇤⇤⇤ 0.19⇤ 0.40⇤⇤⇤ 0.36⇤⇤⇤
1Spearman correlation coefficients: ⇤⇤⇤p<0.0001, ⇤p<0.05
2Greater values indicate greater disease severity
3Greater values indicate better patient health
4Greater values indicate greater interference with daily activities
https://doi.org/10.1371/journal.pone.0194180.t004
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FLU-PRO scores in hospitalized and non-hospitalized patients with ILI. If the instrument per-
forms well, this would facilitate its use in population-level epidemiologic studies and natural
history studies, where laboratory diagnosis of influenza is not always sought or confirmed, and
in studies of patients with influenza-like symptoms but infected with viruses or pathogens
other than influenza.
Results of this study indicate FLU-PRO scores are reliable and reproducible, demonstrate
construct and known-groups validity, and are responsive to change in subjects with ILI. Inter-
nal consistency levels were high for each of the domains and the total score, and 2-day test-
retest reliability levels during the first seven days following enrollment were generally
Table 5. Known-groups validity: FLU-PRO scores by patient global rating of disease severity, Day 1.























Nose 0.89 (0.74) 1.65 (0.98) 2.00 (1.09) 26.9⇤⇤⇤ p<0.001 p<0.001 NS
Throat 0.97 (0.98) 1.48 (0.99) 2.41 (1.21) 32.4⇤⇤⇤ p<0.05 p<0.001 p<0.001
Eyes 0.37 (0.52) 1.04 (0.84) 1.48 (1.18) 30.7⇤⇤⇤ p<0.001 p<0.001 p<0.05
Chest/
Respiratory
1.14 (0.73) 1.42 (0.69) 1.79 (0.93) 12.0⇤⇤⇤ NS p<0.001 p<0.05
Gastrointestinal 0.32 (0.61) 0.38 (0.53) 0.72 (0.89) 6.9⇤⇤ NS p<0.01 p<0.05
Body/Systemic 0.83 (0.65) 1.40 (0.71) 2.15 (0.75) 62.2⇤⇤⇤ p<0.001 p<0.001 p<0.001
Total Score 0.81 (0.45) 1.28 (0.48) 1.84 (0.49) 81.7⇤⇤⇤ p<0.001 p<0.001 p<0.001
1p values are: ⇤⇤<0.01, ⇤⇤⇤<0.001.
Abbreviations: SD = Standard Deviation; NS = Non-significant
https://doi.org/10.1371/journal.pone.0194180.t005
Fig 1. FLU-PRO domain and total score by diary days 1 to 14: Influenza-Negative Patients.
https://doi.org/10.1371/journal.pone.0194180.g001
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moderate to strong. The relatively low test-retest reliability of the Gastrointestinal domain is
due, in part, to the low symptom prevalence and constrained variance. Further evaluation in
patients with influenza strains or pathogens characterized by greater incidence of gastrointesti-
nal distress should be performed, as gastrointestinal symptoms may occur in up to 40% of
patients with influenza [14]. It was interesting to note that score reproducibility was lower dur-
ing the first 2 assessment days in “stable” patients (those reporting “no change” in their symp-
toms). This may be a reflection of the relative nature of “no change” during recovery from an
acute illness, an interpretation that could be explored qualitatively.
As hypothesized and in support of construct validity, FLU-PRO scores were significantly
related to patient global ratings of influenza severity and global health, with patterns and values
similar to those found in the influenza positive sample. Weaker associations were observed
with the patient global rating of interference with activities, as patients may return to usual
activities before total improvement/resolution of symptoms. The data similarly supported
known-groups validity as FLU-PRO scores were lowest in patients rating their symptoms as
the mildest, and increased with increasing patient-reported symptom severity. It was interest-
ing to note that eye, nose, and throat symptoms were more strongly related to flu severity than
respiratory symptoms in milder cases (defined by patient global assessment), with respiratory
symptoms sensitive to differences in the more severe cases. These results suggest the non-
Table 6. Responsiveness of FLU-PRO by patient return to usual health (N = 169)1 and usual activities (N = 117)2, Day 1 to Day 7.
Responders3 Non-Responders
















Usual Health 1.5 (1.0) 0.5 (0.5) 1.0 (0.1) 1.4 (1.0) 0.8 (0.7) 0.7 (0.1) 0.0003
Usual Activities 1.6 (1.1) 0.7 (0.7) 0.7 (0.1) 0.9 (0.8) 0.5 (0.6) 0.7 (0.1) 0.8751
Throat
Usual Health 1.5 (1.1) 0.3 (0.5) 1.2 (0.1) 1.7 (1.3) 0.7 (0.8) 0.9 (0.1) 0.0029
Usual Activities 1.8 (1.2) 0.5 (0.7) 1.1 (0.1) 1.1 (1.2) 0.5 (0.9) 0.9 (0.1) 0.1351
Eyes
Usual Health 0.9 (1.1) 0.1 (0.4) 0.7 (0.1) 0.9 (0.9) 0.3 (0.6) 0.6 (0.0) 0.1202
Usual Activities 1.0 (1.1) 0.2 (0.5) 0.7 (0.1) 0.6 (0.9) 0.2 (0.6) 0.6 (0.1) 0.0919
Chest/Respiratory
Usual Health 1.3 (0.7) 0.5 (0.6) 0.9 (0.1) 1.5 (0.8) 1.0 (0.7) 0.5 (0.1) < .0001
Usual Activities 1.4 (0.8) 0.8 (0.7) 0.7 (0.1) 1.6 (0.8) 0.8 (0.8) 0.7 (0.1) 0.6139
Gastrointestinal
Usual Health 0.4 (0.7) 0.1 (0.3) 0.3 (0.0) 0.4 (0.6) 0.2 (0.4) 0.2 (0.0) 0.0585
Usual Activities 0.4 (0.7) 0.1 (0.2) 0.4 (0.0) 0.4 (0.6) 0.2 (0.5) 0.3 (0.0) 0.0777
Body/Systemic
Usual Health 1.3 (0.9) 0.2 (0.3) 1.2 (0.1) 1.4 (0.9) 0.5 (0.5) 0.9 (0.0) < .0001
Usual Activities 1.6 (0.9) 0.3 (0.4) 1.2 (0.0) 1.1 (0.9) 0.5 (0.5) 0.9 (0.1) 0.0004
Total Score
Usual Health 1.2 (0.6) 0.3 (0.3) 0.9 (0.0) 1.3 (0.6) 0.6 (0.5) 0.7 (0.0) < .0001
Usual Activities 1.4 (0.6) 0.5 (0.4) 0.9 (0.0) 1.1 (0.6) 0.5 (0.5) 0.7 (0.1) 0.0064
1Responders: N = 64; Non-responders: N = 105
2Responders: N = 69; Non-responders: N = 48
3Responders are defined as patients responding that they have returned to their usual health or usual activities at Day 7.
4Analysis of covariance was used to compare changes in FLU-PRO scores at day 7 in responders and non-responders, adjusting for day 1 scores.
https://doi.org/10.1371/journal.pone.0194180.t006
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respiratory domains may be particularly useful in studies of patients with milder influenza-like
illness and to capture the full range of symptom severity. The low prevalence of gastrointestinal
symptoms (relatively high percentage of participants reporting no gastrointestinal symptoms)
would make it more difficult to show significant differences by patient global ratings of influ-
enza severity. Further study in patients with strains or pathogens characterized by gastrointes-
tinal effects are needed.
When responders were defined by reports of return to usual health, the FLU-PRO demon-
strated responsiveness to change from day 1–7. Similar to results observed in the influenza
positive sample, FLU-PRO total and domain scores, except for Eyes and Gastrointestinal, were
responsive to change in the ILI group when return to health was used to define response.
Using return to usual activities as an anchor, responsiveness in ILI patients was shown in the
total and Body/Systemic domain scores.
Comparing current study findings in patients with ILI to influenza-positive patients in the
original validation study sample [10], the FLU-PRO performed similarly in both patient
groups. FLU-PRO domain and total score reliability and reproducibility was supported, with
similar coefficient profiles across domains. Additionally, there were moderate to strong corre-
lations between FLU-PRO domain and total scores and Patient Global Rating of Flu Severity,
Correlations with interference with daily activities were stronger in the laboratory-confirmed
influenza patient population.
Results of this study show the utility of the multi-domain profile scores provided by the
FLU-PRO. Unlike other measures that assess 1 or 2 dimensions of influenza symptom severity
for use in either adults or children [7,8], the FLU-PRO is a comprehensive, multi-dimensional
measure with content intended for use across a wide age spectrum [9]. Its structure yields a
total score, representing symptom severity overall to facilitate hypothesis testing, and separate
assessments of 6 different bodily systems that may be differentially affected by the virus and/or
treatment. For example, the FLUiiQ assesses two domains: respiratory and systemic domains,
with cough, sore throat, and nasal congestion symptoms captured within a single domain [7].
However, the ILI experienced by the patients in the current study was characterized by sore
throat, with less severe respiratory and systemic symptoms than observed in patients testing
positive for the influenza virus. The detailed body system profile can capture these symptoms
which patients stated were important to them [9], and also provide information on where
treatment is and is not providing symptomatic relief.
Gastrointestinal symptoms were experienced by less than 25% of the sample, indicating
these symptoms were not prevalent in the year of this study but have been observed in a greater
proportion of patients in other years with different circulating viral strains. Although this is
technically a floor effect, the results provided quantitative information on the prevalence of
gastrointestinal symptoms in this sample [14]. The Gastrointestinal domain should be
retained, to assure comprehensive symptom assessment across viral strains or pathogens.
While the findings of the current study suggest FLU-PRO scores are reliable, valid, and
responsive in this expanded target population, the study had several limitations. First, although
patients were tested for influenza using RIDTs, the sensitivity and sensitivity of these tests for
detecting influenza A or B can vary, and can differ pending the strain of influenza circulating
during any given year [15,16]. Thus, it is likely that some ILI patients in this study were
infected with influenza A or B. Testing for viruses other than influenza was not available at
most sites, precluding analyses by viral etiology. The FLU-PRO performance can be evaluated
in various specific viral infections in future studies. It is important to note that the purpose of
the FLU-PRO is not to diagnose or to differentiate influenza types. Rather, it is to quantify the
presence and severity of symptoms that are characteristic of various influenza and other respi-
ratory viruses. The FLU-PRO performed well in those testing positive for influenza [10], the
FLU-PRO validation in ILI patients
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primary analyses of the study, with the current study suggesting the performance properties
were comparable in patients presenting to the clinic with a similar set of symptoms but testing
negative for influenza using the RIDT. Second, although hospitalized patients were included in
the analytic sample, details about the hospitalization event (e.g., duration of influenza prior to
hospitalization, acuity level during hospitalization, duration of hospitalization, complicating
comorbid conditions, treatment) are unknown. These can be evaluated in future studies, but
seem unlikely to affect the measurement properties of the instrument, although may result in a
different scoring algorithm. Third, due to sample size limitations, stratified analyses by patient
characteristics (e.g., sex, age) was not performed, but should be considered for future studies.
Finally, while the content validity of the FLU-PRO has been established in children and adoles-
cents through qualitative research, quantitative evaluation of measurement properties has not
been conducted in these patient groups.
Results of this study suggest the FLU-PROmay be useful as an outcome measure in clinical
trials and epidemiological studies of disease due to non-influenza viruses. Although influenza
is often indistinguishable from other viral infections in clinical practice, a standardized com-
prehensive symptom measure may be useful for exploring differences in the presentation and
course of various viral infections. The FLU-PRO may also be used as an inclusion criteria for
studies to ensure patients have sufficient symptoms to test treatment effects and recovery pat-
terns. Future work also may evaluate the use of the FLU-PRO in prevention studies, such as
vaccines, for disease due to various viruses including influenza.
Conclusion
Results of this study suggest FLU-PRO scores are reliable, valid, and responsive to change in
patients testing negative for the influenza virus, indicating the instrument can be used in stud-
ies of confirmed influenza and influenza-like illness.
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